Navigation Links
Elgia Therapeutics Expands Management Team with Appointment of Stacie S. Canan, Ph.D. as Chief Operating Officer
Date:8/26/2020

Elgia Therapeutics, a biotechnology company pursuing novel approaches for the treatment of chronic inflammatory and fibrotic diseases, today announced that Dr. Stacie Canan has joined the company as its Chief Operating Officer and Vice President of Drug Discovery.

Dr. Canan previously served as Executive Director of Global Health at Bristol Myers Squibb (formerly Celgene), and was responsible for Discovery and Development activities on multiple international global health programs for neglected tropical diseases (NTDs). At Celgene, Stacie also served as Executive Director of Chemistry (2007-2012), responsible for chemistry strategy and implementation across the portfolio, including clinical candidate nominations. Stacie has 28 years of experience in the biopharma and pharmaceutical industry, including scientific and leaderships roles at Ligand, Agouron, and Pfizer, with broad expertise that includes project leadership, diverse therapeutic area experience (inflammation/fibrosis, oncology, HIV, HCV, sexual health, ophthalmology and neglected diseases), and success with fragment, structural, phenotypic and property based drug discovery approaches. During her tenure at Agouron, as a member of the discovery team, Stacie co-invented rucaparib (Rubraca®), which is an oral small molecule inhibitor of PARP-1, -2, -3 for treatment of ovarian, fallopian tube, primary peritoneal and mCRP cancers with BRCA mutations.

“We are thrilled to welcome Stacie to our management team,” said Dr. Alan Saltiel, Co-Founder and CEO of Elgia Therapeutics. “Her expertise in drug discovery and deep experience in both the biotech and pharmaceutical industry will be immediately impactful to Elgia’s goal of advancing first-in-class anti-inflammatory and anti-fibrotics into the clinic.”

Dr. Canan received her BS from Pennsylvania State University, MS from University of Illinois and PhD from University of California, Irvine.

About Elgia Therapeutics
Elgia Therapeutics is a newly established venture-backed biotech company pursuing novel approaches for the treatment of chronic inflammatory and fibrotic diseases. Elgia was founded by UCSD and UCSF scientists Alan Saltiel, Ariel Feldstein, Michael Karin, Michelle Arkin, and Adam Renslo, who are world leaders in the biology of innate immunity, inflammation and wound healing, as well as in the biochemistry and pharmacology of key enzymes that control inflammation and cell demise. Leveraging the expertise of our founders, Elgia will use high throughput chemical screening coupled with structure-based design to discover and develop novel inhibitors of these targets. Visit Elgiatherapeutics.com for more information.

About Viva BioInnovator
Viva BioInnovator (VBI) is the investment division of Viva Biotech Holdings (1873.HK). We are solely dedicated to the identification and success of early-stage biotech start-ups for Viva’s incubation, equity-for- service, and investment platforms. Our commitment is to operate a collaborative platform for innovative biotech companies from around the world, and for anyone aiming to develop an idea with transformative or strong potential. Visit vivabioinnovator.com for more information.

Read the full story at https://www.prweb.com/releases/elgia_therapeutics_expands_management_team_with_appointment_of_stacie_s_canan_ph_d_as_chief_operating_officer/prweb17343191.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology news :

1. Jeffrey Modell Foundation supports Belgian research on primary immunodeficiency
2. Johns Hopkins And Belgian research center to expand health care applications for silicon nanotech
3. World Food Prize goes to a Belgian for the first time: The scientist Marc Van Montagu
4. LBA and Hybrid LCMS Quantitation of Biotherapeutics and Biomarkers, Upcoming Webinar Hosted by Xtalks
5. Actuate Therapeutics Announces 9-ING-41 Data Presentation At ASCO Annual Meeting 2020
6. Gritstone Oncology Adopts Genedata Biopharma Platform to Accelerate Development of TCR and Bispecific Antibody Therapeutics
7. Cytonus Therapeutics Announces Christopher Thorne as Chairman
8. VetStem Biopharma Enters Pet Cancer Field with Key License from Leading Human Cancer Company, Calidi Biotherapeutics
9. Orbsen Therapeutics Moves Into New Headquarters in Galway, Ireland
10. Nativis Announces Name Change To EMulate Therapeutics, Inc.
11. uBiome Receives Patent for Microbiome-Derived Diagnostics and Therapeutics for Immune-Microbial Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/5/2020)... Fla. (PRWEB) , ... August 05, 2020 , ... Regenative ... cover two new innovations, CoreText™ and ProText™, making them the first Wharton’s jelly allografts ... defect using a syringe. The company’s solutions are the first Wharton’s jelly allograft product ...
(Date:7/31/2020)... ... July 30, 2020 , ... BioFactura, Inc. ... awarded by the Joint Science & Technology Office—Chemical and Biological Defense (JSTO-CBD) of ... optimize, and scale-up a highly efficient mammalian cell culture-based bioprocess suitable to meet ...
(Date:7/22/2020)... ... July 21, 2020 , ... USDM Life Sciences ... compliance, announces a new solution to manage regulated workloads on Microsoft Azure. , ... technology stack complies with FDA and global regulations. USDM's new managed service for ...
Breaking Biology News(10 mins):
(Date:7/10/2020)... HONG KONG (PRWEB) , ... July 09, 2020 ... ... chemical compound called 1-phenyl-2-thiourea (PTU) is commonly used to suppress pigment formation in ... years, the PolyU research team led by Dr MA has been using the ...
(Date:7/7/2020)... ... July 06, 2020 , ... R3 International is now offering ... to 200 million stem cells. Depending on the patient's condition, treatment may be offered ... will die having some form of Alzheimers dementia, and the incidence continues to increase ...
(Date:7/1/2020)... ... June 29, 2020 , ... MedShift , ... in 2020, despite many obstacles created as a result of COVID-19. As a ... its partnered medical practices and medical manufacturers by expanding access to device offerings, ...
(Date:7/1/2020)... ... June 30, 2020 , ... ... announced that the launch of a new clinical diagnostics immuno-oncology service, ... tumor microenvironment (TME). , “Flagship’s TissueInsight is a service that aids pathologists, ...
Breaking Biology Technology: